Osteoporosis International

, Volume 19, Issue 4, pp 479–491

Salmon calcitonin: a review of current and future therapeutic indications

Authors

    • Osteoporosis Research GroupUniversity of Washington
  • M. Azria
    • Novartis Pharma AG
  • S. Silverman
    • Department of Medicine and RheumatologyCedars Sinai Medical Center
  • M. Engelhardt
    • Novartis Pharma AG
  • M. Olson
    • Novartis Pharma AG
  • L. Mindeholm
    • Novartis Pharma AG
Review

DOI: 10.1007/s00198-007-0490-1

Cite this article as:
Chesnut, C.H., Azria, M., Silverman, S. et al. Osteoporos Int (2008) 19: 479. doi:10.1007/s00198-007-0490-1

Abstract

Salmon calcitonin, available as a therapeutic agent for more than 30 years, demonstrates clinical utility in the treatment of such metabolic bone diseases as osteoporosis and Paget's disease, and potentially in the treatment of osteoarthritis. This review considers the physiology and pharmacology of salmon calcitonin, the evidence based research demonstrating efficacy and safety of this medication in postmenopausal osteoporosis with potentially an effect on bone quality to explain its abilities to reduce the risk of spine fracture, the development of an oral salmon calcitonin preparation, and the therapeutic rationale for this preparation's chondroprotective effect in osteoarthritis.

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2007